Firstly, we adapted and established a published 48-hour RT-QuIC protocol, including the in-house production of recombinant α-synuclein (rec α-syn), and evaluated its sensitivity and specificity through a blinded screening of an 81 CSF sample cohort consisting of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), Alzheimer’s disease, motor neuron disease, multiple system atrophy, unidentified neurodegenerative diseases, and healthy controls. This evidence concerns the gene SNCA and Parkinson disease.